- Home
- PIM vs HUMA Comparison
PIM vs HUMA Comparison
Compare PIM & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | HUMA |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 134.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIM | HUMA |
|---|---|---|
| Price | $3.30 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.44 |
| AVG Volume (30 Days) | 149.8K | ★ 9.9M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,075.22 |
| Revenue Next Year | N/A | $290.51 |
| P/E Ratio | $66.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $0.55 |
| 52 Week High | $3.50 | $2.93 |
Technical Indicators
Market Signals| Indicator | PIM | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 34.49 |
| Support Level | $3.28 | N/A |
| Resistance Level | $3.38 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 79.22 | 17.19 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.